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Abstract. Daily injections of insulin provide lifesaving benefits to 
millions of diabetics. But currently available prandial insulins are 
suboptimal: The onset of action is delayed by slow dissociation of 
the insulin hexamer in the subcutaneous space, and insulin forms 
amyloid fibrils upon storage in solution. Here we show, through 
the use of non-canonical amino acid mutagenesis, that 
replacement of the proline residue at position 28 of the insulin B-
chain (ProB28) by (4S)-hydroxyproline (Hzp) yields an active 
form of insulin that dissociates more rapidly, and fibrillates more 
slowly, than the wild-type protein. Crystal structures of dimeric 
and hexameric insulin preparations suggest that a hydrogen bond 
between the hydroxyl group of Hzp and a backbone amide 
carbonyl positioned across the dimer interface may be responsible 
for the altered behavior. The effects of hydroxylation are 
stereospecific; replacement of ProB28 by (4R)-hydroxyproline 
(Hyp) causes little change in the rates of fibrillation and hexamer 
disassociation. These results demonstrate a new approach that 
fuses the concepts of medicinal chemistry and protein design, and 
paves the way to further engineering of insulin and other 
therapeutic proteins. 
Blood glucose levels are tightly controlled in mammals through 
a sensitive regulatory system mediated by insulin, a 51-amino 
acid endocrine hormone composed of two disulfide-linked 
polypeptide chains (designated A and B). Upon binding to its 
receptor, insulin initiates a signaling cascade that accelerates 
glucose uptake and glycogen production. In diabetic patients, this 
system malfunctions, and glucose levels must be controlled 
through subcutaneous injections of insulin1. The C-terminus of 
the B-chain is important in mediating dimerization of the 
hormone2-3, and the flexibility of the B-chain C-terminus is 
believed to contribute to aggregation through formation of 
amyloid fibrils4-6. Pharmaceutical formulations of insulin are 
stabilized with respect to fibrillation by addition of zinc and 
phenolic preservatives, which drive assembly of the R6 hexamer 
(Fig. 1a)7-9.  The R6 form of insulin is inactive and dissociates 
slowly to its active monomeric form after subcutaneous injection; 
the lag time for dissociation delays the onset of action10. Mutation 
of ProB28 yields rapid-acting insulins (RAIs) by disrupting 
contacts that are critical for dimer formation8, but replacement of 
Pro through conventional mutagenesis also increases the 
flexibility and perturbs the trajectory of the protein backbone 
(Fig. 1B). We sought a means to disrupt the dimer interface 
without releasing the conformational constraints characteristic of 
proline by using non-canonical amino acid (ncAA) mutagenesis11-
13. Specifically, we introduced hydroxyl groups at the 4-position 
of ProB28 (Fig. 1B, C) by replacing Pro with Hzp or Hyp. In 
addition to introducing a polar functional group and the capacity 
for hydrogen-bonding (including transannular hydrogen bonding), 
hydroxylation at the 4-position is known to alter the endo/exo 
preference of the pyrrolidine ring and the cis/trans equilibrium of 
the backbone amide bond14-16. 
We expressed modified proinsulins (PIs) in the proline-
auxotrophic E. coli strain CAG18515 in M9 minimal media 
supplemented with Hyp or Hzp. The extent of replacement of Pro 
by either Hyp or Hzp was approximately 90%17-18 as determined 
by matrix-assisted laser desorption/ionization mass spectrometry 
(MALDI-MS; fig. S1). Denatured PIs were purified by Ni-NTA 
affinity chromatography in yields of 32 mg/L for Hzp-PI and 29 
mg/L for Hyp-PI (table S1) from the inclusion body fraction. The 
PIs were refolded and cleaved with trypsin and carboxypeptidase 
B19.  The resulting mature insulins were purified by reversed 
phase HPLC18-19, and proper proteolytic processing of each 
variant was verified by MALDI-MS (table S1). Wild-type insulin 
(ProI) and RAI Aspart (AspI, in which ProB28 is replaced by 
aspartic acid) were produced similarly. All of the variants caused 
similar reductions in blood glucose upon subcutaneous injection 
into diabetic mice (Fig. 1D)2, 20-22.  RAIs cannot be distinguished 
from ProI in rodent models23. 
In the absence of Zn2+ and phenolic preservatives, insulins 
dimerize with a dissociation constant (KD) of approximately 10 
µM.  In contrast, KD for RAIs is typically >500 µM, and it is 
believed that destabilization of the dimer interface causes the 
accelerated onset of insulin action after subcutaneous injection20, 
24-25. Monomeric forms of insulin give rise to characteristic 
circular dichroism (CD) spectra with distinct minima at 208 and 
222 nm26-27 (e.g., AspI; Fig. 2A). Dimerization causes a loss of 
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Figure. 1. Hydroxyinsulins retain activity. (A) Schematic of hexamer disassembly (adapted from mechanism previously described 8). 
Phenolic ligand (Ph), zinc ion (Zn2+), insulin monomer (triangle). Darker shading indicates the R-state of the hexamer. (B) Structures of 
the B-chain C-termini of wild-type insulin (ProI) and RAI Aspart (AspI). (C) Chemical structures of L-proline (1), (2S,4S)-hydroxyproline 
(Hzp; 2), (2S,4R)-hydroxyproline (Hyp; 3). (D) Reduction of blood glucose following subcutaneous injection of 35 µg/kg insulins into 
streptozotocin-induced diabetic mice. Glucose levels were measured post-injection via tail vein sampling. ProI, AspI, HzpI, HypI or vector 
were formulated as described 22. Error bars denote one standard deviation (n = 3). 
Figure. 2. Hydroxylation at ProB28 modulates insulin dimerization, dissociation kinetics, and stability. (A) Far UV CD spectra 
collected on 60 µM insulins in 10 mM phosphate buffer, pH 8.0 at 25°C. (B) Insulin hexamer dissociation following sequestration of Zn2+ 
by terpyridine.  Zn2+-(terpy) signal was monitored at 334 nm and fitted to a mono-exponential decay. HzpI and HypI contain 10% ProI. 
The curves for HypI and ProI are indistinguishable in this plot. (C) Representative fibrillation curves for 60 µM insulins (37°C, 960 RPM; 
n=4). Insulin fibrils were detected by the rise in Thioflavin T (ThT) fluorescence that accompanies binding to fibrillar aggregates. 
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Figure. 3. Crystal structures of HzpI and HypI. In tan (left), wt insulins from PDB (3T2A, 1ZNJ) highlighting the distance between the 
carbon atom at the 4th position of ProB28 and its closest neighbors, backbone carbonyl oxygen atoms of GlyB20’ and GluB21 in the T2 
dimer (A) and R6 hexamer (D) forms.  In grey (middle), HzpI in the T2 dimer (B) and R6 hexamer (E) forms. In blue (right), HypI in the T2 
dimer (C) and R6 hexamer (F) forms. 
negative ellipticity at 208 nm27 (e.g., ProI; Fig. 2A). At a 
concentration of 60 µM, HypI appears to be monomeric (with a 
CD spectrum nearly identical to that of AspI; Fig. 2A) while the 
spectrum of HzpI suggests a dimeric insulin (Fig. 2A). 
Sedimentation velocity (SV) and sedimentation equilibrium (SE) 
experiments were consistent with the results of the CD analysis 
(fig. S3). SE data were fitted to a model of monomer-dimer-
hexamer self-association (SEDPHAT) 28-29, and yielded 
monomer-dimer dissociation constants (KD) of >200 µM and 25 
µM for HypI and HzpI, respectively. 
Previous studies of RAIs have shown that destabilization of the 
dimer interface correlates with accelerated dissociation of the 
hexamer and rapid onset of insulin action8, 13.  Triggered 
dissociation of Zn2+-hexamers by addition of terpyridine30 
revealed nearly identical rates of dissociation for HypI and ProI, 
(1/2 = 87.0 ± 10 s and 90.4 ± 4.2 s, respectively; Fig. 2B and fig. 
S4) while HzpI exhibited kinetics similar to those of AspI (1/2 = 
53.6 ± 3.7 s and 42.7 ± 4.3 s, respectively; Fig. 2B and fig. S4).  
We found these results surprising – replacement of Pro by Hyp 
destabilizes the dimer but has essentially no effect on hexamer 
dissociation, while introduction of Hzp causes little change in 
dimer stability but a substantial increase in the rate of hexamer 
disassembly. 
Each of the insulin variants was subjected to fibrillation lag 
time analysis (Fig. 2C)31. We found similar times to onset of 
fibrillation for HypI, ProI and AspI; in contrast, HzpI is markedly 
more resistant to aggregation, with a mean time to onset more 
than three-fold longer than that observed for ProI. The behavior of 
HzpI is especially striking, in that it combines fast hexamer 
dissociation with enhanced stability toward fibrillation. 
Each subunit in the insulin hexamer adopts one of two 
conformational states (T or R), depending on the concentration of 
phenolic ligand (Fig. 1A)13. Pharmaceutical formulations are 
prepared in the more stable R6 form, whereas the T-state is 
observed in the absence of phenolic ligands, most commonly in 
the form of T2-dimers
32. To elucidate the molecular origins of the 
dissociation and fibrillation behavior of HypI and HzpI, we 
examined crystal structures of both states. 
 
Hydroxylation at ProB28 does not cause substantial 
perturbation of the overall insulin structure (Fig. 3, fig. S5).  In 
comparison with ProI, the backbone RMSD values of HypI and 
HzpI are 0.31 Å (T2- HypI), 0.44 Å (T2- HypI), 0.38 Å (R6- HypI) 
and 0.69 Å (R6- HypI)
33. The most notable feature of the HzpI 
structures is the proximity of the hydroxyl group of Hzp to the 
backbone carbonyl oxygen atom of GluB21′, which lies across the 
dimer interface (denoted by prime; Fig. 3B, E). The inter-oxygen 
distances (2.8 Å in the T2 structure, 2.7 Å in R6), are consistent 
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with the formation of strong hydrogen bonds between the 
hydroxyl group of HzpB28 and the backbone carbonyl of GluB21′ 
in both structures. An analogous hydrogen bond has been 
observed in a structure (PDB ID: 1ZEH) of R6-AspI co-
crystallized with m-cresol34; here the phenolic ligand serves as the 
hydrogen-bond donor (fig. S6). Although the significance of this 
hydrogen bond has not been discussed in the literature, we 
suggest that it may play an important role in determining the 
relative stabilities of the insulin species involved in dissociation 
and fibrillation.  In contrast to the (4S)-hydroxyl group of Hzp, 
the (4R)-hydroxyl of HypB28 does not contact any 
crystallographically resolved hydrogen bond acceptor in the T2-
structure (Fig. 3C), and appears to bond to an ordered water 
molecule in the R6-hexamer (Fig. 3F). The absence of new 
hydrogen-bonding interactions is consistent with the unaltered 
dissociation and fibrillation kinetics of HypI.  
Taken together, our results show that replacement of Pro by 
Hzp at position 28 of the insulin B-chain introduces a new 
hydrogen bond across the inter-subunit interface, accelerates 
hexamer dissociation and delays the onset of fibrillation (Table 
1). We suggest that the hydrogen bond between Hzp and Glu21′ 
may stabilize the dimer relative to the hexamer, or perhaps reduce 
the energy of the transition state for the conformational change 
from the R-state to T-state, and thereby speed disassembly. The 
delayed onset of fibrillation may reflect changes in the structure 
and dynamics of the HzpI monomer or in the kinetics of fibril 
nucleation. Subtle conformational effects caused by 4S-
substitution on the pyrrolidine ring may also contribute to the 
observed behavior.35 Whether or not these hypotheses are correct, 
the results described here demonstrate the power of ncAA 
mutagenesis to control functionally relevant biophysical 
properties of therapeutic proteins. We anticipate that this 
approach will find increasing application in the design of 
antibody-drug conjugates, bispecific antibodies, and other novel 
protein therapeutics.  
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